Breast Cancer

After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.

Dr. Sheri Yolanda Prentiss discusses lymphedema as a result of cancer treatment and shares resources that exist for patients coping with this condition.

Dr. Sheri Yolanda Prentiss explores the challenges patients face in accessing lymphedema compression garments following cancer treatment.

I tried using a Zen garden that helped me meditate and relax while dealing with the challenges of cancer, and it really works.

Lessons I learned from a cancer diagnosis have been applied in some surprising and seemingly unrelated aspects of my life.

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for further treatment expansion.

Eleven years post diagnosis and issues related to breast cancer still frustrate me.

I reflect on how cancer has brought out resilience and support in others, even as I struggled with my own battle, and wish others strength in their journeys.

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Cancer memories often sneak up on me when I least expect them to.

Survivors facing new medical concerns may fear the unknown, but perseverance is possible as they navigate unexpected challenges in their new normal.

Dr. Regina Hampton shares case studies from her own practice, illustrating how genomic insights have improved patient outcomes in those with breast cancer.

Dr. Debu Tripathy explains how ctDNA is used to in breast cancer detection and how it can also indicate the presence of MRD.

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.

Cancer runs in the family, and after I’d dealt with two breast cancers, my brother came down with lymphoma.

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.

As a breast cancer survivor, I feel it is incumbent upon me to give an accurate picture of cancer to others, particularly newly diagnosed patients.

Dr. Regina Hampton highlighted unmet needs in black women with breast cancer and details how genomic information can drive effective treatment options.

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved from cancer.

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.

Practicing consistency has made a difference for me while living with stage 4 breast cancer.

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.